XtalPi and Sedec Therapeutics announces the collaboration of novel therapeutics development against autoimmune diseases

XtalPi 2021-09-15

XtalPi and Sedec have recently reached an agreement to develop novel small-molecule therapeutics targeting STAT3 palmitoylation pathway for auto immune disorder diseases treatment.

Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor that regulates diverse biological processes, such as cell proliferation, differentiation, apoptosis, angiogenesis, inflammation, and immune responses. Sedec has identified a breakthrough in targeting STAT3 palmitoylation to inhibit STAT3 and treat autoimmune diseases [1]. STAT3 is a key regulator in TH17 cell differentiation, which plays a crucial role in multiple autoimmune diseases. Sedec aims to develop potent small-molecule drugs to modulate the STAT3 palmitoylation pathway, which have exciting potential in therapeutic applications in autoimmune diseases such as Ulcerative Colitis, Psoriatic Arthritis, Crohn’s Disease, Multiple Sclerosis, and many more. It is believed to have great market potentials of up to $3 billion [2].

XtalPi’s proprietary one-stop drug discovery solution integrating quantum physics-based computation, artificial intelligence, cloud computing and wet lab experimentation to redefine drug discovery, will facilitate complete workflow by iterating Design-Make-Test-Analyze (DMTA) cycle efficiently. Molecules with outstanding properties in biological activity, selectivity, ADME and safety will be generated, meanwhile, novelty in molecule backbone is also guaranteed. Compared to conventional drug discovery workflow, “AI-based computation + experimentation” drug discovery model from XtalPi, reduces the number of molecules to be synthesized and accelerates drug discovery with high success rates.

Sedec is a leader in protein palmitoylation pathways-targeted therapeutic development. With support of state-of-the-art technologies from XtalPi, Sedec is strongly focused on deliver new small-molecule therapies in the field. Leveraging technological expertise from both sides to further extend and strengthen mutual capabilities in pathway-targeted therapeutic discovery is expected to yield rich dividends in this collaboration.

“XtalPi’s expertise in computational chemistry and AI-enabled drug-discovery platform could help us with the small-molecule drug design and greatly accelerate the lead optimization process. We have a project that is well suited for AI-enabled drug-discovery platform and the collaboration between Sedec and XtalPi could provide useful knowledge and insight that will benefit future drug discovery in other areas”, commented Professor Hening Lin, founder and scientific advisor of Sedec Therapeutics.

“Professor Lin and his team have achieved great success in target identification in the crucial auto-immune disease related pathway. XtalPi will leverage our integrated AI-empowered drug discovery and our continuous improved capability in experiments to provide the total solution from target to PCC to our collaborators, which can be applied to more R&D projects and therapeutic areas,” Dr. Jian Man, CEO of XtalPi commented.


About XtalPi

XtalPi is a digitalization driven, AI-empowered drug research and development company. Based on expertise in quantum physics, quantum chemistry, artificial intelligence, and cloud computation technology, XtalPi is aiming to provide intelligent drug discovery service to pioneer pharmaceutical companies globally with improved efficiency and success rates in critical steps while reducing cost, facilitating clients to provide high quality therapeutics to patients.

Founded in the MIT campus, XtalPi is now a global organization with pioneering team expertized across artificial intelligence, computational chemistry from academic fields and pharmaceutical industry. With headquarter located in Shenzhen, branches in Beijing, Shanghai and Boston, XtalPi has been providing drug discovery services to over 70 pharmaceutical clients worldwide.


About Sedec Therapeutics

Sedec is focused on innovative therapeutics to modulate the immune cell system in autoimmune diseases and cancer immunotherapies. By centering our technology on the protein palmitoylation/depalmitoylation pathway, Sedec’s mission is to translate our unique biological breakthrough into a new generation of therapeutics for patients. Sedec is founded by Dr. Hening Lin, Professor at Cornell University and HHMI Investigator, and receives investment and incubation support from Plaisance Capital. With R&D laboratory located at Natick, MA, Sedec’s core team is composed of experienced scientists with PhD degrees from Cornell University, University of Chicago, Harvard University, and seasoned biotech investors and entrepreneurs.     



  1. Zhang M, et al. A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis . Naturevolume 586, pages434–439 (2020)
  2. https://www.researchandmarkets.com/reports/4564280/global-anti-inflammatory-therapeutics-market


More News

XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target

SHENZHEN, China & BOSTON - Signet Therapeutics and XtalPi Inc., a physics-based, AI-powered drug R&D company, announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet. The two companies entered into a strategic collaboration in 2020 and successfully identified pre-clinical candidates for a new gastric cancer target in approximately six months. The follow-on project will continue to combine XtalPi’s AI drug discovery platform with Signet’s unique novel organoid disease models to generate pipeline candidates and advance them toward clinical trials.

Research Collaboration between XtalPi Inc and Acerand Therapeutics to develop potential novel anti-cancer therapies using High-precision Physics-based model and Machine Learning

XtalPi, a leading AI drug discovery company, announces a research collaboration with Acerand Therapeutics, a biotechnology company specialized in developing best-in-class and or first-in-class drugs. The partnership will leverage XtalPi's highly accurate physics-based models and machine learning models to develop potential novel chemical entities for a cancer target.

XtalPi Invests in Novel Target Discovery Biotech PhoreMost in Oversubscribed Series B Financing

CAMBRIDGE, Mass., March 23, 2021 -- XtalPi, an artificial intelligence (AI) drug discovery and development company, is pleased to announce its investment in the Series B financing of PhoreMost, a UK-based biopharmaceutical company dedicated to Drugging the Undruggable disease targets. The investment round totaled $46 million and was led by BGF, with participation from XtalPi and a panel of new and existing investors. XtalPi Chief Strategy Officer (CSO) Dr. Alan Jiang will join PhoreMost Board of Directors.